메뉴 건너뛰기




Volumn 6, Issue 4, 2014, Pages 838-851

Antibodies directed against receptor tyrosine kinases: Current and future strategies to fight cancer

Author keywords

ADC; Antibody drug conjugate; Bispecific antibody; Cancer therapy; Receptor tyrosine kinase; Unconjugated antibody

Indexed keywords

BISPECIFIC ANTIBODY; CETUXIMAB; DOCETAXEL; EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR; INSULIN RECEPTOR; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PANITUMUMAB; PERTUZUMAB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RON RECEPTOR TYROSINE KINASE; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; EGFR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

EID: 84903784528     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.29089     Document Type: Review
Times cited : (60)

References (156)
  • 2
    • 33746836894 scopus 로고    scopus 로고
    • Targeted therapy of cancer: New prospects for antibodies and immunoconjugates
    • PMID:16870998
    • Sharkey RM, Goldenberg DM. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates. CA Cancer J Clin 2006; 56:226-43; PMID:16870998; http://dx.doi.org/10.3322/canjclin.56.4.226
    • (2006) CA Cancer J Clin , vol.56 , pp. 226-243
    • Sharkey, R.M.1    Goldenberg, D.M.2
  • 3
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the ErbB signalling network
    • PMID:11252954
    • Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073
    • (2001) Nat Rev Mol Cell Biol , vol.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.X.2
  • 4
    • 84890041471 scopus 로고    scopus 로고
    • The ErbB/HER family of protein-tyrosine kinases and cancer
    • PMID:24269963
    • Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res 2014; 79:34-74; PMID:24269963; http://dx.doi.org/10.1016/ j.phrs.2013.11.002
    • (2014) Pharmacol Res , vol.79 , pp. 34-74
    • Roskoski Jr., R.1
  • 5
    • 34347395733 scopus 로고    scopus 로고
    • Trastuzumab - Mechanism of action and use in clinical practice
    • PMID:17611206
    • Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/ NEJMra043186
    • (2007) N Engl J Med , vol.357 , pp. 39-51
    • Hudis, C.A.1
  • 6
    • 0032895235 scopus 로고    scopus 로고
    • Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
    • PMID:10211534
    • Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-18; PMID:10211534; http://dx.doi.org/10.1016/ S0149-2918(00)88288-0
    • (1999) Clin Ther , vol.21 , pp. 309-318
    • Goldenberg, M.M.1
  • 7
    • 84876266920 scopus 로고    scopus 로고
    • Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer
    • PMID:23227361
    • Nahta R. Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol 2012; 2012:428062; PMID:23227361; http://dx.doi.org/10.5402/2012/428062
    • (2012) ISRN Oncol , vol.2012 , pp. 428062
    • Nahta, R.1
  • 8
    • 68249157963 scopus 로고    scopus 로고
    • Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts
    • PMID:19617342
    • McLarty K, Cornelissen B, Cai Z, Scollard DA, Costantini DL, Done SJ, Reilly RM. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009; 50:1340-8; PMID:19617342; http://dx.doi.org/10.2967/jnumed.109.062224
    • (2009) J Nucl Med , vol.50 , pp. 1340-1348
    • McLarty, K.1    Cornelissen, B.2    Cai, Z.3    Scollard, D.A.4    Costantini, D.L.5    Done, S.J.6    Reilly, R.M.7
  • 9
    • 79952162826 scopus 로고    scopus 로고
    • HER2-amplified breast cancer: Mechanisms of trastuzumab resistance and novel targeted therapies
    • PMID:21342044
    • Gajria D, Chandarlapaty S. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther 2011; 11:263-75; PMID:21342044; http://dx.doi.org/10.1586/era.10.226
    • (2011) Expert Rev Anticancer Ther , vol.11 , pp. 263-275
    • Gajria, D.1    Chandarlapaty, S.2
  • 10
    • 0035874898 scopus 로고    scopus 로고
    • Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2
    • PMID:11406568
    • Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA, Lipkowitz S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 2001; 61:4892-900; PMID:11406568
    • (2001) Cancer Res , vol.61 , pp. 4892-4900
    • Cuello, M.1    Ettenberg, S.A.2    Clark, A.S.3    Keane, M.M.4    Posner, R.H.5    Nau, M.M.6    Dennis, P.A.7    Lipkowitz, S.8
  • 13
    • 0034473365 scopus 로고    scopus 로고
    • New insights into anti-HER-2 receptor monoclonal antibody research
    • discussion 92-100; PMID:11236033
    • Kumar R, Mandal M, Vadlamudi R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin Oncol 2000; 27(Suppl 11):84-91, discussion 92-100; PMID:11236033
    • (2000) Semin Oncol , vol.27 , Issue.SUPPL. 11 , pp. 84-91
    • Kumar, R.1    Mandal, M.2    Vadlamudi, R.3
  • 14
    • 0037099532 scopus 로고    scopus 로고
    • Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
    • PMID:12124352
    • Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 2002; 62:4132-41; PMID:12124352
    • (2002) Cancer Res , vol.62 , pp. 4132-4141
    • Yakes, F.M.1    Chinratanalab, W.2    Ritter, C.A.3    King, W.4    Seelig, S.5    Arteaga, C.L.6
  • 15
    • 35848945096 scopus 로고    scopus 로고
    • Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines
    • PMID:17938260
    • Emlet DR, Brown KA, Kociban DL, Pollice AA, Smith CA, Ong BBL, Shackney SE. Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines. Mol Cancer Ther 2007; 6:2664-74; PMID:17938260; http://dx.doi.org/10.1158/1535-7163.MCT-07-0079
    • (2007) Mol Cancer Ther , vol.6 , pp. 2664-2674
    • Emlet, D.R.1    Brown, K.A.2    Kociban, D.L.3    Pollice, A.A.4    Smith, C.A.5    Ong, B.B.L.6    Shackney, S.E.7
  • 16
    • 67649472398 scopus 로고    scopus 로고
    • Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3
    • PMID:19536107
    • Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9:463-75; PMID:19536107; http://dx.doi.org/10.1038/nrc2656
    • (2009) Nat Rev Cancer , vol.9 , pp. 463-475
    • Baselga, J.1    Swain, S.M.2
  • 18
    • 33644600485 scopus 로고    scopus 로고
    • Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
    • PMID:16151804
    • Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006; 55:717-27; PMID:16151804; http://dx.doi.org/10.1007/s00262-005-0058-x
    • (2006) Cancer Immunol Immunother , vol.55 , pp. 717-727
    • Adams, C.W.1    Allison, D.E.2    Flagella, K.3    Presta, L.4    Clarke, J.5    Dybdal, N.6    McKeever, K.7    Sliwkowski, M.X.8
  • 19
    • 67651174452 scopus 로고    scopus 로고
    • Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
    • PMID:19584234
    • Hughes JB, Berger C, Rødland MS, Hasmann M, Stang E, Madshus IH. Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization. Mol Cancer Ther 2009; 8:1885-92; PMID:19584234; http://dx.doi.org/10.1158/1535-7163. MCT-09-0291
    • (2009) Mol Cancer Ther , vol.8 , pp. 1885-1892
    • Hughes, J.B.1    Berger, C.2    Rødland, M.S.3    Hasmann, M.4    Stang, E.5    Madshus, I.H.6
  • 20
    • 84886390059 scopus 로고    scopus 로고
    • Pertuzumab: Optimizing HER2 blockade
    • PMID:23942091
    • Metzger-Filho O, Winer EP, Krop I. Pertuzumab: optimizing HER2 blockade. Clin Cancer Res 2013; 19:5552-6; PMID:23942091; http://dx.doi.org/10.1158/1078- 0432.CCR-13-0518
    • (2013) Clin Cancer Res , vol.19 , pp. 5552-5556
    • Metzger-Filho, O.1    Winer, E.P.2    Krop, I.3
  • 21
    • 48649092620 scopus 로고    scopus 로고
    • A central role for HER3 in HER2-amplified breast cancer: Implications for targeted therapy
    • PMID:18632642
    • Lee-Hoeflich ST, Crocker L, Yao E, Pham T, Munroe X, Hoeflich KP, Sliwkowski MX, Stern HM. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 2008; 68:5878-87; PMID:18632642; http://dx.doi.org/10.1158/0008-5472.CAN-08-0380
    • (2008) Cancer Res , vol.68 , pp. 5878-5887
    • Lee-Hoeflich, S.T.1    Crocker, L.2    Yao, E.3    Pham, T.4    Munroe, X.5    Hoeflich, K.P.6    Sliwkowski, M.X.7    Stern, H.M.8
  • 23
    • 73649149433 scopus 로고    scopus 로고
    • Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models
    • PMID:19934333
    • Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597
    • (2009) Cancer Res , vol.69 , pp. 9330-9336
    • Scheuer, W.1    Friess, T.2    Burtscher, H.3    Bossenmaier, B.4    Endl, J.5    Hasmann, M.6
  • 24
    • 84887005800 scopus 로고    scopus 로고
    • Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3
    • PMID:23698633
    • Sak MM, Szymanska M, Bertelsen V, Hasmann M, Madshus IH, Stang E. Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3. Carcinogenesis 2013; 34:2031-8; PMID:23698633; http://dx.doi.org/10.1093/carcin/ bgt173
    • (2013) Carcinogenesis , vol.34 , pp. 2031-2038
    • Sak, M.M.1    Szymanska, M.2    Bertelsen, V.3    Hasmann, M.4    Madshus, I.H.5    Stang, E.6
  • 25
    • 84860390489 scopus 로고    scopus 로고
    • Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: An in silico based mechanism
    • PMID:21600050
    • Fuentes G, Scaltriti M, Baselga J, Verma CS. Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanism. Breast Cancer Res 2011; 13:R54; PMID:21600050; http://dx.doi.org/10.1186/bcr2888
    • (2011) Breast Cancer Res , vol.13
    • Fuentes, G.1    Scaltriti, M.2    Baselga, J.3    Verma, C.S.4
  • 26
    • 84880210838 scopus 로고    scopus 로고
    • EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    • PMID:23837762
    • Kao H-F, Lin C-C, Yang JC-H. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol 2013; 9:991-1003; PMID:23837762; http://dx.doi.org/10.2217/fon.13.56
    • (2013) Future Oncol , vol.9 , pp. 991-1003
    • Kao, H.-F.1    Lin, C.-C.2    Yang, J.C.-H.3
  • 27
    • 84877998630 scopus 로고    scopus 로고
    • Recent advances in drug design of epidermal growth factor receptor inhibitors
    • PMID:23410174
    • Warnault P, Yasri A, Coisy-Quivy M, Chevé G, Boriès C, Fauvel B, Benhida R. Recent advances in drug design of epidermal growth factor receptor inhibitors. Curr Med Chem 2013; 20:2043-67; PMID:23410174; http://dx.doi.org/10.2174/0929867311320160001
    • (2013) Curr Med Chem , vol.20 , pp. 2043-2067
    • Warnault, P.1    Yasri, A.2    Coisy-Quivy, M.3    Chevé, G.4    Boriès, C.5    Fauvel, B.6    Benhida, R.7
  • 28
    • 7444266703 scopus 로고    scopus 로고
    • Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer
    • PMID:15314969
    • Krawczyk P, Chocholska S, Milanowski J. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer. Ann Univ Mariae Curie Sklodowska Med 2003; 58:113-7; PMID:15314969
    • (2003) Ann Univ Mariae Curie Sklodowska Med , vol.58 , pp. 113-117
    • Krawczyk, P.1    Chocholska, S.2    Milanowski, J.3
  • 29
    • 60749095127 scopus 로고    scopus 로고
    • Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation
    • PMID:19082474
    • Patel D, Bassi R, Hooper A, Prewett M, Hicklin DJ, Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int J Oncol 2009; 34:25-32; PMID:19082474
    • (2009) Int J Oncol , vol.34 , pp. 25-32
    • Patel, D.1    Bassi, R.2    Hooper, A.3    Prewett, M.4    Hicklin, D.J.5    Kang, X.6
  • 30
    • 0028819660 scopus 로고
    • Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
    • PMID:9815926
    • Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-8; PMID:9815926
    • (1995) Clin Cancer Res , vol.1 , pp. 1311-1318
    • Goldstein, N.I.1    Prewett, M.2    Zuklys, K.3    Rockwell, P.4    Mendelsohn, J.5
  • 31
    • 0032972944 scopus 로고    scopus 로고
    • Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
    • PMID:10037173
    • Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve BY, Hicklin DJ, Radinsky R, Dinney CP. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999; 5:257-65; PMID:10037173
    • (1999) Clin Cancer Res , vol.5 , pp. 257-265
    • Perrotte, P.1    Matsumoto, T.2    Inoue, K.3    Kuniyasu, H.4    Eve, B.Y.5    Hicklin, D.J.6    Radinsky, R.7    Dinney, C.P.8
  • 32
    • 34347229786 scopus 로고    scopus 로고
    • Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor
    • PMID:17498200
    • Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007; 98:1275-80; PMID:17498200; http://dx.doi.org/10.1111/j.1349-7006.2007.00510.x
    • (2007) Cancer Sci , vol.98 , pp. 1275-1280
    • Kimura, H.1    Sakai, K.2    Arao, T.3    Shimoyama, T.4    Tamura, T.5    Nishio, K.6
  • 33
    • 77953046198 scopus 로고    scopus 로고
    • Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
    • PMID:20529262
    • Hsu Y-F, Ajona D, Corrales L, Lopez-Picazo JM, Gurpide A, Montuenga LM, Pio R. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo. Mol Cancer 2010; 9:139; PMID:20529262; http://dx.doi.org/10.1186/1476-4598-9-139
    • (2010) Mol Cancer , vol.9 , pp. 139
    • Hsu, Y.-F.1    Ajona, D.2    Corrales, L.3    Lopez-Picazo, J.M.4    Gurpide, A.5    Montuenga, L.M.6    Pio, R.7
  • 34
    • 35948961556 scopus 로고    scopus 로고
    • The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines
    • PMID:17962339
    • Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson WE 3rd. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007; 13:6419-28; PMID:17962339; http://dx.doi.org/10.1158/1078-0432.CCR-07-0865
    • (2007) Clin Cancer Res , vol.13 , pp. 6419-6428
    • Roda, J.M.1    Joshi, T.2    Butchar, J.P.3    McAlees, J.W.4    Lehman, A.5    Tridandapani, S.6    Carson III, W.E.7
  • 35
    • 84871368013 scopus 로고    scopus 로고
    • Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel
    • PMID:23213241
    • Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF. Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel. Proc Natl Acad Sci U S A 2012; 109:21046-51; PMID:23213241; http://dx.doi.org/10.1073/pnas.1218750110
    • (2012) Proc Natl Acad Sci U S A , vol.109 , pp. 21046-21051
    • Ashraf, S.Q.1    Nicholls, A.M.2    Wilding, J.L.3    Ntouroupi, T.G.4    Mortensen, N.J.5    Bodmer, W.F.6
  • 36
    • 0036820993 scopus 로고    scopus 로고
    • Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme
    • discussion 1013-4; PMID:12234411
    • Eller JL, Longo SL, Hicklin DJ, Canute GW. Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery 2002; 51:1005-13, discussion 1013-4; PMID:12234411
    • (2002) Neurosurgery , vol.51 , pp. 1005-1013
    • Eller, J.L.1    Longo, S.L.2    Hicklin, D.J.3    Canute, G.W.4
  • 37
    • 84865409125 scopus 로고    scopus 로고
    • In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype
    • PMID:22011788
    • Hotz B, Keilholz U, Fusi A, Buhr HJ, Hotz HG. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype. Gastric Cancer 2012; 15:252-64; PMID:22011788; http://dx.doi.org/10.1007/s10120- 011-0102-9
    • (2012) Gastric Cancer , vol.15 , pp. 252-264
    • Hotz, B.1    Keilholz, U.2    Fusi, A.3    Buhr, H.J.4    Hotz, H.G.5
  • 38
    • 0033561522 scopus 로고    scopus 로고
    • Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck
    • PMID:10213503
    • Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999; 59:1935-40; PMID:10213503
    • (1999) Cancer Res , vol.59 , pp. 1935-1940
    • Huang, S.M.1    Bock, J.M.2    Harari, P.M.3
  • 40
    • 84862026304 scopus 로고    scopus 로고
    • Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
    • PMID:22446022
    • Bokemeyer C, Van Cutsem E, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Köhne C-H. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 2012; 48:1466-75; PMID:22446022; http://dx.doi.org/10.1016/j.ejca.2012.02.057
    • (2012) Eur J Cancer , vol.48 , pp. 1466-1475
    • Bokemeyer, C.1    Van Cutsem, E.2    Rougier, P.3    Ciardiello, F.4    Heeger, S.5    Schlichting, M.6    Celik, I.7    Köhne, C.-H.8
  • 41
    • 77957716587 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab
    • PMID:20923247
    • Yang B-B, Lum P, Chen A, Arends R, Roskos L, Smith B, Pérez Ruixo JJ. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin Pharmacokinet 2010; 49:729-40; PMID:20923247; http://dx.doi.org/10.2165/11535970-000000000-00000
    • (2010) Clin Pharmacokinet , vol.49 , pp. 729-740
    • Yang, B.-B.1    Lum, P.2    Chen, A.3    Arends, R.4    Roskos, L.5    Smith, B.6    Pérez Ruixo, J.J.7
  • 45
    • 78650597089 scopus 로고    scopus 로고
    • IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab
    • PMID:21178280
    • Patel D, Guo X, Ng S, Melchior M, Balderes P, Burtrum D, Persaud K, Luna X, Ludwig DL, Kang X. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19:89-99; PMID:21178280
    • (2010) Hum Antibodies , vol.19 , pp. 89-99
    • Patel, D.1    Guo, X.2    Ng, S.3    Melchior, M.4    Balderes, P.5    Burtrum, D.6    Persaud, K.7    Luna, X.8    Ludwig, D.L.9    Kang, X.10
  • 46
    • 73949155239 scopus 로고    scopus 로고
    • Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage
    • PMID:19949082
    • Schneider-Merck T, Lammerts van Bueren JJ, Berger S, Rossen K, van Berkel PHC, Derer S, Beyer T, Lohse S, Bleeker WK, Peipp M, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010; 184:512-20; PMID:19949082; http://dx.doi.org/10.4049/jimmunol.0900847
    • (2010) J Immunol , vol.184 , pp. 512-520
    • Schneider-Merck, T.1    Lammerts Van Bueren, J.J.2    Berger, S.3    Rossen, K.4    Van Berkel, P.H.C.5    Derer, S.6    Beyer, T.7    Lohse, S.8    Bleeker, W.K.9    Peipp, M.10
  • 48
    • 79251646160 scopus 로고    scopus 로고
    • Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer
    • PMID:21169348
    • Doi T, Tahara M, Yoshino T, Yamazaki K, Tamura T, Yamada Y, Yang B-B, Oliner KS, Otani S, Asahi D. Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer. Jpn J Clin Oncol 2011; 41:210-6; PMID:21169348; http://dx.doi.org/10.1093/jjco/hyq229
    • (2011) Jpn J Clin Oncol , vol.41 , pp. 210-216
    • Doi, T.1    Tahara, M.2    Yoshino, T.3    Yamazaki, K.4    Tamura, T.5    Yamada, Y.6    Yang, B.-B.7    Oliner, K.S.8    Otani, S.9    Asahi, D.10
  • 49
    • 84891120865 scopus 로고    scopus 로고
    • Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer
    • PMID:24381645
    • Hocking CM, Price TJ. Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therap Adv Gastroenterol 2014; 7:20-37; PMID:24381645; http://dx.doi.org/10.1177/1756283X13498660
    • (2014) Therap Adv Gastroenterol , vol.7 , pp. 20-37
    • Hocking, C.M.1    Price, T.J.2
  • 50
    • 84894592709 scopus 로고    scopus 로고
    • KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model
    • PMID:24558511
    • Kumar SS, Price TJ, Mohyieldin O, Borg M, Townsend A, Hardingham JE. KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model. Gastrointest Cancer Res 2014; 7:23-6; PMID:24558511
    • (2014) Gastrointest Cancer Res , vol.7 , pp. 23-26
    • Kumar, S.S.1    Price, T.J.2    Mohyieldin, O.3    Borg, M.4    Townsend, A.5    Hardingham, J.E.6
  • 51
    • 0037145332 scopus 로고    scopus 로고
    • Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody
    • PMID:12237899
    • Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567-75; PMID:12237899; http://dx.doi.org/10.1002/ijc.10647
    • (2002) Int J Cancer , vol.101 , pp. 567-575
    • Crombet-Ramos, T.1    Rak, J.2    Pérez, R.3    Viloria-Petit, A.4
  • 52
    • 68949146819 scopus 로고    scopus 로고
    • Nimotuzumab: A novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
    • PMID:19624281
    • Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9:1199-206; PMID:19624281; http://dx.doi.org/10.1517/ 14712590903110709
    • (2009) Expert Opin Biol Ther , vol.9 , pp. 1199-1206
    • Boland, W.K.1    Bebb, G.2
  • 55
    • 84898895006 scopus 로고    scopus 로고
    • Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    • PMID:24142531
    • Su D, Jiao S-C, Wang L-J, Shi W-W, Long Y-Y, Li J, Bai L. Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. Tumour Biol 2014; 35:2313-8; PMID:24142531; http://dx.doi.org/10.1007/s13277-013-1306-x
    • (2014) Tumour Biol , vol.35 , pp. 2313-2318
    • Su, D.1    Jiao, S.-C.2    Wang, L.-J.3    Shi, W.-W.4    Long, Y.-Y.5    Li, J.6    Bai, L.7
  • 57
    • 38949118663 scopus 로고    scopus 로고
    • Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8
    • PMID:18275813
    • Li S, Kussie P, Ferguson KM. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16:216-27; PMID:18275813; http://dx.doi.org/10.1016/j.str.2007.11.009
    • (2008) Structure , vol.16 , pp. 216-227
    • Li, S.1    Kussie, P.2    Ferguson, K.M.3
  • 58
    • 79952752582 scopus 로고    scopus 로고
    • Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer
    • PMID:21154125
    • Dienstmann R, Tabernero J. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer. Curr Opin Investig Drugs 2010; 11:1434-41; PMID:21154125
    • (2010) Curr Opin Investig Drugs , vol.11 , pp. 1434-1441
    • Dienstmann, R.1    Tabernero, J.2
  • 60
    • 84862513344 scopus 로고    scopus 로고
    • Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy
    • PMID:22659454
    • Gan HK, Burgess AW, Clayton AHA, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 2012; 72:2924-30; PMID:22659454; http://dx.doi.org/ 10.1158/0008-5472.CAN-11-3898
    • (2012) Cancer Res , vol.72 , pp. 2924-2930
    • Gan, H.K.1    Burgess, A.W.2    Clayton, A.H.A.3    Scott, A.M.4
  • 61
    • 76549085643 scopus 로고    scopus 로고
    • Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy
    • PMID:20068188
    • Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 2010; 70:588-97; PMID:20068188; http://dx.doi.org/10.1158/0008-5472.CAN-09-1417
    • (2010) Cancer Res , vol.70 , pp. 588-597
    • Pedersen, M.W.1    Jacobsen, H.J.2    Koefoed, K.3    Hey, A.4    Pyke, C.5    Haurum, J.S.6    Kragh, M.7
  • 63
    • 82255167636 scopus 로고    scopus 로고
    • Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
    • PMID:22129105
    • Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res 2011; 13:R123; PMID:22129105; http://dx.doi.org/10.1186/bcr3069
    • (2011) Breast Cancer Res , vol.13
    • Nordstrom, J.L.1    Gorlatov, S.2    Zhang, W.3    Yang, Y.4    Huang, L.5    Burke, S.6    Li, H.7    Ciccarone, V.8    Zhang, T.9    Stavenhagen, J.10
  • 65
    • 84873370707 scopus 로고    scopus 로고
    • Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function
    • PMID:23224399
    • Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL. Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res 2013; 19:610-9; PMID:23224399; http://dx.doi.org/10. 1158/1078-0432.CCR-12-2024
    • (2013) Clin Cancer Res , vol.19 , pp. 610-619
    • Garrett, J.T.1    Sutton, C.R.2    Kuba, M.G.3    Cook, R.S.4    Arteaga, C.L.5
  • 66
  • 67
    • 84885049277 scopus 로고    scopus 로고
    • Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers
    • PMID:23918797
    • Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL. Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Cancer Res 2013; 73:6013-23; PMID:23918797; http://dx.doi.org/10.1158/0008-5472.CAN-13-1191
    • (2013) Cancer Res , vol.73 , pp. 6013-6023
    • Garrett, J.T.1    Sutton, C.R.2    Kurupi, R.3    Bialucha, C.U.4    Ettenberg, S.A.5    Collins, S.D.6    Sheng, Q.7    Wallweber, J.8    Defazio-Eli, L.9    Arteaga, C.L.10
  • 68
    • 84903781817 scopus 로고    scopus 로고
    • Abstract 2718: REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers
    • Zhang L, Luan B, Yang K, Castanaro C, Papadopoulos N, Thurston G, Daly C. Abstract 2718: REGN1400, a fully-human ERBB3 antibody, potently inhibits tumor growth in preclinical models, both as a monotherapy and in combination with EGFR or HER2 blockers. Cancer Res 2012; 72:2718-2718; http://dx.doi.org/10.1158/ 1538-7445.AM2012-2718
    • (2012) Cancer Res , vol.72 , pp. 2718-2718
    • Zhang, L.1    Luan, B.2    Yang, K.3    Castanaro, C.4    Papadopoulos, N.5    Thurston, G.6    Daly, C.7
  • 69
    • 84887389563 scopus 로고    scopus 로고
    • The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
    • PMID:24215614
    • Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer 2013; 12:134; PMID:24215614; http://dx.doi.org/10.1186/1476-4598-12-134
    • (2013) Mol Cancer , vol.12 , pp. 134
    • Huang, J.1    Wang, S.2    Lyu, H.3    Cai, B.4    Yang, X.5    Wang, J.6    Liu, B.7
  • 70
    • 84886436005 scopus 로고    scopus 로고
    • Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
    • PMID:24168763
    • Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee C-K, et al. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Res 2013; 15:R101; PMID:24168763; http://dx.doi.org/10.1186/ bcr3563
    • (2013) Breast Cancer Res , vol.15
    • Wang, S.1    Huang, J.2    Lyu, H.3    Cai, B.4    Yang, X.5    Li, F.6    Tan, J.7    Edgerton, S.M.8    Thor, A.D.9    Lee, C.-K.10
  • 71
    • 84882679616 scopus 로고    scopus 로고
    • RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation
    • PMID:23780344
    • Mirschberger C, Schiller CB, Schräml M, Dimoudis N, Friess T, Gerdes CA, Reiff U, Lifke V, Hoelzlwimmer G, Kolm I, et al. RG7116, a therapeutic antibody that binds the inactive HER3 receptor and is optimized for immune effector activation. Cancer Res 2013; 73:5183-94; PMID:23780344; http://dx.doi.org/10.1158/0008-5472.CAN-13-0099
    • (2013) Cancer Res , vol.73 , pp. 5183-5194
    • Mirschberger, C.1    Schiller, C.B.2    Schräml, M.3    Dimoudis, N.4    Friess, T.5    Gerdes, C.A.6    Reiff, U.7    Lifke, V.8    Hoelzlwimmer, G.9    Kolm, I.10
  • 72
    • 84881542709 scopus 로고    scopus 로고
    • The emerging role of MET/HGF inhibitors in oncology
    • PMID:23453860
    • Scagliotti GV, Novello S, von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013; 39:793-801; PMID:23453860; http://dx.doi.org/10.1016/j.ctrv.2013.02.001
    • (2013) Cancer Treat Rev , vol.39 , pp. 793-801
    • Scagliotti, G.V.1    Novello, S.2    Von Pawel, J.3
  • 73
    • 23044497596 scopus 로고    scopus 로고
    • Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: Potential as EphA3-specific tumor-targeting reagents
    • PMID:16061656
    • Vearing C, Lee F-T, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents. Cancer Res 2005; 65:6745-54; PMID:16061656; http://dx.doi.org/10.1158/0008-5472.CAN-05-0758
    • (2005) Cancer Res , vol.65 , pp. 6745-6754
    • Vearing, C.1    Lee, F.-T.2    Wimmer-Kleikamp, S.3    Spirkoska, V.4    To, C.5    Stylianou, C.6    Spanevello, M.7    Brechbiel, M.8    Boyd, A.W.9    Scott, A.M.10
  • 75
    • 0038697632 scopus 로고    scopus 로고
    • How to make tubes: Signaling by the Met receptor tyrosine kinase
    • PMID:12791299
    • Rosário M, Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol 2003; 13:328-35; PMID:12791299; http://dx.doi.org/10.1016/S0962-8924(03)00104-1
    • (2003) Trends Cell Biol , vol.13 , pp. 328-335
    • Rosário, M.1    Birchmeier, W.2
  • 76
    • 76549109409 scopus 로고    scopus 로고
    • Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma
    • PMID:20068147
    • Davis IJ, McFadden AW, Zhang Y, Coxon A, Burgess TL, Wagner AJ, Fisher DE. Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. Cancer Res 2010; 70:639-45; PMID:20068147; http://dx.doi.org/10.1158/0008-5472.CAN-09- 1121
    • (2010) Cancer Res , vol.70 , pp. 639-645
    • Davis, I.J.1    McFadden, A.W.2    Zhang, Y.3    Coxon, A.4    Burgess, T.L.5    Wagner, A.J.6    Fisher, D.E.7
  • 77
    • 49249100382 scopus 로고    scopus 로고
    • MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
    • PMID:18519697
    • Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RAD, Kasman I, Mai E, Young J, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-8; PMID:18519697; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960
    • (2008) Cancer Res , vol.68 , pp. 4360-4368
    • Jin, H.1    Yang, R.2    Zheng, Z.3    Romero, M.4    Ross, J.5    Bou-Reslan, H.6    Carano, R.A.D.7    Kasman, I.8    Mai, E.9    Young, J.10
  • 78
    • 84881405670 scopus 로고    scopus 로고
    • Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent
    • PMID:23882082
    • Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A 2013; 110:E2987-96; PMID:23882082; http://dx.doi.org/10.1073/pnas.1302725110
    • (2013) Proc Natl Acad Sci U S A , vol.110
    • Merchant, M.1    Ma, X.2    Maun, H.R.3    Zheng, Z.4    Peng, J.5    Romero, M.6    Huang, A.7    Yang, N.Y.8    Nishimura, M.9    Greve, J.10
  • 80
    • 84887497121 scopus 로고    scopus 로고
    • The quest to overcome resistance to EGFR-targeted therapies in cancer
    • PMID:24202392
    • Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19:1389-400; PMID:24202392; http://dx.doi.org/10.1038/nm.3388
    • (2013) Nat Med , vol.19 , pp. 1389-1400
    • Chong, C.R.1    Jänne, P.A.2
  • 81
    • 84908293893 scopus 로고    scopus 로고
    • Abstract 2448: H224G11, a humanized whole antibody targeting the c-Met receptor, induces c-Met down-regulation and triggers ADCC functions
    • Goetsch L, Broussas M, Fabre-Lafay S, Robert A, Lepecquet A-M, Gonzalez A, Wurch T, Bailly C, Corvaia N. Abstract 2448: h224G11, a humanized whole antibody targeting the c-Met receptor, induces c-Met down-regulation and triggers ADCC functions. Cancer Res 2011; 70:2448-2448; http://dx.doi.org/10. 1158/1538-7445.AM10-2448
    • (2011) Cancer Res , vol.70 , pp. 2448-2448
    • Goetsch, L.1    Broussas, M.2    Fabre-Lafay, S.3    Robert, A.4    Lepecquet, A.-M.5    Gonzalez, A.6    Wurch, T.7    Bailly, C.8    Corvaia, N.9
  • 82
    • 84896733569 scopus 로고    scopus 로고
    • Abstract 2734: C-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer
    • Zeng W, Yan L, Peek V, Wortinger M, Tetreault J, Xia J, Chow C-K, Manro JR, Stephens JR, Weir SN, et al. Abstract 2734: c-Met antibody LY2875358 (LA480) shows differential antitumor effects in non-small cell lung cancer. Cancer Res 2012; 72:2734-2734; http://dx.doi.org/10.1158/1538-7445.AM2012-2734
    • (2012) Cancer Res , vol.72 , pp. 2734-2734
    • Zeng, W.1    Yan, L.2    Peek, V.3    Wortinger, M.4    Tetreault, J.5    Xia, J.6    Chow, C.-K.7    Manro, J.R.8    Stephens, J.R.9    Weir, S.N.10
  • 84
    • 84881089423 scopus 로고    scopus 로고
    • MSP-RON signalling in cancer: Pathogenesis and therapeutic potential
    • PMID:23792360
    • Yao H-P, Zhou Y-Q, Zhang R, Wang M-H. MSP-RON signalling in cancer: pathogenesis and therapeutic potential. Nat Rev Cancer 2013; 13:466-81; PMID:23792360; http://dx.doi.org/10.1038/nrc3545
    • (2013) Nat Rev Cancer , vol.13 , pp. 466-481
    • Yao, H.-P.1    Zhou, Y.-Q.2    Zhang, R.3    Wang, M.-H.4
  • 85
    • 77956379695 scopus 로고    scopus 로고
    • Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy
    • PMID:20694025
    • Wang M-H, Padhye SS, Guin S, Ma Q, Zhou YQ. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy. Acta Pharmacol Sin 2010; 31:1181-8; PMID:20694025; http://dx.doi.org/10.1038/aps.2010.106
    • (2010) Acta Pharmacol Sin , vol.31 , pp. 1181-1188
    • Wang, M.-H.1    Padhye, S.S.2    Guin, S.3    Ma, Q.4    Zhou, Y.Q.5
  • 86
    • 84880785380 scopus 로고    scopus 로고
    • Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi)
    • PMID:23922886
    • Zou Y, Howell GM, Humphrey LE, Wang J, Brattain MG. Ron knockdown and Ron monoclonal antibody IMC-RON8 sensitize pancreatic cancer to histone deacetylase inhibitors (HDACi). PLoS One 2013; 8:e69992; PMID:23922886; http://dx.doi.org/10.1371/journal.pone.0069992
    • (2013) PLoS One , vol.8
    • Zou, Y.1    Howell, G.M.2    Humphrey, L.E.3    Wang, J.4    Brattain, M.G.5
  • 87
    • 33846807433 scopus 로고    scopus 로고
    • Disrupting insulin-like growth factor signaling as a potential cancer therapy
    • PMID:17237261
    • Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6:1-12; PMID:17237261; http://dx.doi.org/10.1158/1535-7163.MCT-06-0080
    • (2007) Mol Cancer Ther , vol.6 , pp. 1-12
    • Sachdev, D.1    Yee, D.2
  • 88
    • 0029692479 scopus 로고    scopus 로고
    • The role of the insulin-like growth factor system in human cancer
    • PMID:8712068
    • Werner H, LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 1996; 68:183-223; PMID:8712068; http://dx.doi.org/10.1016/S0065-230X(08)60354-1
    • (1996) Adv Cancer Res , vol.68 , pp. 183-223
    • Werner, H.1    LeRoith, D.2
  • 89
    • 0032909323 scopus 로고    scopus 로고
    • The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors
    • PMID:10235470
    • Grothey A, Voigt W, Schöber C, Müller T, Dempke W, Schmoll HJ. The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 1999; 125:166-73; PMID:10235470; http://dx.doi.org/10.1007/ s004320050259
    • (1999) J Cancer Res Clin Oncol , vol.125 , pp. 166-173
    • Grothey, A.1    Voigt, W.2    Schöber, C.3    Müller, T.4    Dempke, W.5    Schmoll, H.J.6
  • 90
    • 84863900275 scopus 로고    scopus 로고
    • Insulin-like growth factor receptor inhibitors: Baby or the bathwater?
    • PMID:22761272
    • Yee D. Insulin-like growth factor receptor inhibitors: baby or the bathwater? J Natl Cancer Inst 2012; 104:975-81; PMID:22761272; http://dx.doi.org/10.1093/jnci/djs258
    • (2012) J Natl Cancer Inst , vol.104 , pp. 975-981
    • Yee, D.1
  • 91
    • 34848903049 scopus 로고    scopus 로고
    • IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor
    • PMID:17875788
    • Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 2007; 13:5549s-55s; PMID:17875788; http://dx.doi.org/10.1158/1078-0432.CCR-07-1109
    • (2007) Clin Cancer Res , vol.13
    • Rowinsky, E.K.1    Youssoufian, H.2    Tonra, J.R.3    Solomon, P.4    Burtrum, D.5    Ludwig, D.L.6
  • 92
    • 66849140937 scopus 로고    scopus 로고
    • AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
    • PMID:19366899
    • Beltran PJ, Mitchell P, Chung Y-A, Cajulis E, Lu J, Belmontes B, Ho J, Tsai MM, Zhu M, Vonderfecht S, et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol Cancer Ther 2009; 8:1095-105; PMID:19366899; http://dx.doi.org/10.1158/1535-7163.MCT-08-1171
    • (2009) Mol Cancer Ther , vol.8 , pp. 1095-1105
    • Beltran, P.J.1    Mitchell, P.2    Chung, Y.-A.3    Cajulis, E.4    Lu, J.5    Belmontes, B.6    Ho, J.7    Tsai, M.M.8    Zhu, M.9    Vonderfecht, S.10
  • 93
    • 84855398829 scopus 로고    scopus 로고
    • Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology
    • PMID:22215692
    • Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012; 72:3-12; PMID:22215692; http://dx.doi.org/10.1158/0008-5472.CAN-11-0550
    • (2012) Cancer Res , vol.72 , pp. 3-12
    • Gao, J.1    Chang, Y.S.2    Jallal, B.3    Viner, J.4
  • 94
    • 77953193972 scopus 로고    scopus 로고
    • Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer
    • PMID:20521225
    • Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010; 12:361-71; PMID:20521225
    • (2010) Curr Opin Mol Ther , vol.12 , pp. 361-371
    • Scartozzi, M.1    Bianconi, M.2    Maccaroni, E.3    Giampieri, R.4    Berardi, R.5    Cascinu, S.6
  • 95
    • 57749121465 scopus 로고    scopus 로고
    • The EphA2 receptor and ephrinA1 ligand in solid tumors: Function and therapeutic targeting
    • PMID:19074825
    • Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6:1795-806; PMID:19074825; http://dx.doi.org/10.1158/1541-7786.MCR-08-0244
    • (2008) Mol Cancer Res , vol.6 , pp. 1795-1806
    • Wykosky, J.1    Debinski, W.2
  • 96
    • 84871053738 scopus 로고    scopus 로고
    • Eph receptors and ephrins as targets for cancer therapy
    • PMID:22862837
    • Xi H-Q, Wu X-S, Wei B, Chen L. Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med 2012; 16:2894-909; PMID:22862837; http://dx.doi.org/10.1111/j.1582-4934.2012.01612.x
    • (2012) J Cell Mol Med , vol.16 , pp. 2894-2909
    • Xi, H.-Q.1    Wu, X.-S.2    Wei, B.3    Chen, L.4
  • 97
    • 84861524407 scopus 로고    scopus 로고
    • Targeting of EPH receptor tyrosine kinases for anticancer therapy
    • PMID:22471709
    • Nievergall E, Saunders T, Lackmann M. Targeting of EPH receptor tyrosine kinases for anticancer therapy. Crit Rev Oncog 2012; 17:211-32; PMID:22471709; http://dx.doi.org/10.1615/CritRevOncog.v17.i2.60
    • (2012) Crit Rev Oncog , vol.17 , pp. 211-232
    • Nievergall, E.1    Saunders, T.2    Lackmann, M.3
  • 98
    • 84891703635 scopus 로고    scopus 로고
    • Therapeutic targeting of EPH receptors and their ligands
    • PMID:24378802
    • Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov 2014; 13:39-62; PMID:24378802; http://dx.doi.org/10.1038/nrd4175
    • (2014) Nat Rev Drug Discov , vol.13 , pp. 39-62
    • Boyd, A.W.1    Bartlett, P.F.2    Lackmann, M.3
  • 99
    • 84888427862 scopus 로고    scopus 로고
    • Targeted inhibition of VEGF receptor 2: An update on ramucirumab
    • PMID:23803182
    • Clarke JM, Hurwitz HI. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther 2013; 13:1187-96; PMID:23803182; http://dx.doi.org/10.1517/14712598.2013.810717
    • (2013) Expert Opin Biol Ther , vol.13 , pp. 1187-1196
    • Clarke, J.M.1    Hurwitz, H.I.2
  • 100
    • 84871633270 scopus 로고    scopus 로고
    • Vascular endothelial growth factor and its receptor system: Physiological functions in angiogenesis and pathological roles in various diseases
    • PMID:23172303
    • Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013; 153:13-9; PMID:23172303; http://dx.doi.org/10.1093/jb/ mvs136
    • (2013) J Biochem , vol.153 , pp. 13-19
    • Shibuya, M.1
  • 101
    • 76249106934 scopus 로고    scopus 로고
    • Vascular endothelial growth factor receptor-1 in human cancer: Concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)
    • PMID:20127948
    • Schwartz JD, Rowinsky EK, Youssoufian H, Pytowski B, Wu Y. Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010; 116(Suppl):1027-32; PMID:20127948; http://dx.doi.org/10.1002/cncr.24789
    • (2010) Cancer , vol.116 , Issue.SUPPL. , pp. 1027-1032
    • Schwartz, J.D.1    Rowinsky, E.K.2    Youssoufian, H.3    Pytowski, B.4    Wu, Y.5
  • 102
    • 67650674112 scopus 로고    scopus 로고
    • Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer
    • PMID:19513949
    • Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009; 10:597-605; PMID:19513949
    • (2009) Curr Opin Investig Drugs , vol.10 , pp. 597-605
    • Krupitskaya, Y.1    Wakelee, H.A.2
  • 103
    • 70349277438 scopus 로고    scopus 로고
    • Monoclonal antibodies targeting vascular endothelial growth factor: Current status and future challenges in cancer therapy
    • PMID:19754219
    • Hsu JY, Wakelee HA. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. BioDrugs 2009; 23:289-304; PMID:19754219; http://dx.doi.org/10.2165/11317600-000000000- 00000
    • (2009) BioDrugs , vol.23 , pp. 289-304
    • Hsu, J.Y.1    Wakelee, H.A.2
  • 104
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial
    • REGARD Trial Investigators PMID:24094768
    • Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, et al.; REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383:31-9; PMID:24094768; http://dx.doi.org/10.1016/S0140-6736(13)61719-5
    • (2014) Lancet , vol.383 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3    Dumitru, F.4    Passalacqua, R.5    Goswami, C.6    Safran, H.7    Dos Santos, L.V.8    Aprile, G.9    Ferry, D.R.10
  • 105
    • 84901301933 scopus 로고    scopus 로고
    • A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy
    • Forthcoming; PMID:24577874
    • Garcia JA, Hudes GR, Choueiri TK, Stadler WM, Wood LS, Gurtler J, Bhatia S, Joshi A, Hozak RR, Xu Y, et al. A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy. Cancer 2014; (Forthcoming); PMID:24577874; http://dx.doi.org/10.1002/cncr.28634
    • (2014) Cancer
    • Garcia, J.A.1    Hudes, G.R.2    Choueiri, T.K.3    Stadler, W.M.4    Wood, L.S.5    Gurtler, J.6    Bhatia, S.7    Joshi, A.8    Hozak, R.R.9    Xu, Y.10
  • 106
    • 80855140942 scopus 로고    scopus 로고
    • Tanibirumab (TTAC-0001): A fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2)
    • PMID:21910042
    • Lee SH. Tanibirumab (TTAC-0001): a fully human monoclonal antibody targets vascular endothelial growth factor receptor 2 (VEGFR-2). Arch Pharm Res 2011; 34:1223-6; PMID:21910042; http://dx.doi.org/10.1007/s12272-011-0821-9
    • (2011) Arch Pharm Res , vol.34 , pp. 1223-1226
    • Lee, S.H.1
  • 107
    • 78649992510 scopus 로고    scopus 로고
    • Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization
    • PMID:21130043
    • Tvorogov D, Anisimov A, Zheng W, Leppänen V-M, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, et al. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010; 18:630-40; PMID:21130043; http://dx.doi.org/10.1016/j.ccr.2010.11.001
    • (2010) Cancer Cell , vol.18 , pp. 630-640
    • Tvorogov, D.1    Anisimov, A.2    Zheng, W.3    Leppänen, V.-M.4    Tammela, T.5    Laurinavicius, S.6    Holnthoner, W.7    Heloterä, H.8    Holopainen, T.9    Jeltsch, M.10
  • 108
    • 3042587472 scopus 로고    scopus 로고
    • Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C
    • PMID:15150322
    • Persaud K, Tille J-C, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao H-Q, Brennan LA, Witte L, Pepper MS, et al. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci 2004; 117:2745-56; PMID:15150322; http://dx.doi.org/10.1242/jcs.01138
    • (2004) J Cell Sci , vol.117 , pp. 2745-2756
    • Persaud, K.1    Tille, J.-C.2    Liu, M.3    Zhu, Z.4    Jimenez, X.5    Pereira, D.S.6    Miao, H.-Q.7    Brennan, L.A.8    Witte, L.9    Pepper, M.S.10
  • 110
    • 84879313697 scopus 로고    scopus 로고
    • The C-kit receptor-mediated signal transduction and tumor-related diseases
    • PMID:23678293
    • Liang J, Wu Y-L, Chen B-J, Zhang W, Tanaka Y, Sugiyama H. The C-kit receptor-mediated signal transduction and tumor-related diseases. Int J Biol Sci 2013; 9:435-43; PMID:23678293; http://dx.doi.org/10.7150/ijbs.6087
    • (2013) Int J Biol Sci , vol.9 , pp. 435-443
    • Liang, J.1    Wu, Y.-L.2    Chen, B.-J.3    Zhang, W.4    Tanaka, Y.5    Sugiyama, H.6
  • 111
    • 34047127376 scopus 로고    scopus 로고
    • PDGF receptors as targets in tumor treatment
    • PMID:17419949
    • Ostman A, Heldin C-H. PDGF receptors as targets in tumor treatment. Adv Cancer Res 2007; 97:247-74; PMID:17419949; http://dx.doi.org/10.1016/S0065- 230X(06)97011-0
    • (2007) Adv Cancer Res , vol.97 , pp. 247-274
    • Ostman, A.1    Heldin, C.-H.2
  • 112
    • 76249126427 scopus 로고    scopus 로고
    • Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha
    • PMID:20127943
    • Shah GD, Loizos N, Youssoufian H, Schwartz JD, Rowinsky EK. Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 2010; 116(Suppl):1018-26; PMID:20127943; http://dx.doi.org/10.1002/cncr. 24788
    • (2010) Cancer , vol.116 , Issue.SUPPL. , pp. 1018-1026
    • Shah, G.D.1    Loizos, N.2    Youssoufian, H.3    Schwartz, J.D.4    Rowinsky, E.K.5
  • 113
    • 84896053860 scopus 로고    scopus 로고
    • A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
    • PMID:24452395
    • Chiorean EG, Sweeney C, Youssoufian H, Qin A, Dontabhaktuni A, Loizos N, Nippgen J, Amato R. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2014; 73:595-604; PMID:24452395; http://dx.doi.org/10.1007/s00280-014-2389-9
    • (2014) Cancer Chemother Pharmacol , vol.73 , pp. 595-604
    • Chiorean, E.G.1    Sweeney, C.2    Youssoufian, H.3    Qin, A.4    Dontabhaktuni, A.5    Loizos, N.6    Nippgen, J.7    Amato, R.8
  • 114
    • 84876048479 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor inhibitors as a cancer treatment: From a biologic rationale to medical perspectives
    • PMID:23418312
    • Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013; 3:264-79; PMID:23418312; http://dx.doi.org/10. 1158/2159-8290.CD-12-0362
    • (2013) Cancer Discov , vol.3 , pp. 264-279
    • Dieci, M.V.1    Arnedos, M.2    Andre, F.3    Soria, J.C.4
  • 115
    • 84866736540 scopus 로고    scopus 로고
    • Anticancer molecules targeting fibroblast growth factor receptors
    • PMID:22884522
    • Liang G, Liu Z, Wu J, Cai Y, Li X. Anticancer molecules targeting fibroblast growth factor receptors. Trends Pharmacol Sci 2012; 33:531-41; PMID:22884522; http://dx.doi.org/10.1016/j.tips.2012.07.001
    • (2012) Trends Pharmacol Sci , vol.33 , pp. 531-541
    • Liang, G.1    Liu, Z.2    Wu, J.3    Cai, Y.4    Li, X.5
  • 116
    • 72049092008 scopus 로고    scopus 로고
    • De-regulated FGF receptors as therapeutic targets in cancer
    • PMID:19874848
    • Knights V, Cook SJ. De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 2010; 125:105-17; PMID:19874848; http://dx.doi.org/10. 1016/j.pharmthera.2009.10.001
    • (2010) Pharmacol Ther , vol.125 , pp. 105-117
    • Knights, V.1    Cook, S.J.2
  • 117
    • 84889080157 scopus 로고    scopus 로고
    • Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers
    • PMID:23900974
    • Tiong KH, Mah LY, Leong C-O. Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers. Apoptosis 2013; 18:1447-68; PMID:23900974; http://dx.doi.org/10.1007/s10495-013-0886-7
    • (2013) Apoptosis , vol.18 , pp. 1447-1468
    • Tiong, K.H.1    Mah, L.Y.2    Leong, C.-O.3
  • 118
    • 84875456598 scopus 로고    scopus 로고
    • Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy
    • PMID:23467610
    • Gerald D, Chintharlapalli S, Augustin HG, Benjamin LE. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res 2013; 73:1649-57; PMID:23467610; http://dx.doi.org/10.1158/0008-5472.CAN-12-4697
    • (2013) Cancer Res , vol.73 , pp. 1649-1657
    • Gerald, D.1    Chintharlapalli, S.2    Augustin, H.G.3    Benjamin, L.E.4
  • 119
    • 84879115397 scopus 로고    scopus 로고
    • Targeting angiopoietin-2 signaling in cancer therapy
    • PMID:23621441
    • Eroglu Z, Stein CA, Pal SK. Targeting angiopoietin-2 signaling in cancer therapy. Expert Opin Investig Drugs 2013; 22:813-25; PMID:23621441; http://dx.doi.org/10.1517/13543784.2013.793306
    • (2013) Expert Opin Investig Drugs , vol.22 , pp. 813-825
    • Eroglu, Z.1    Stein, C.A.2    Pal, S.K.3
  • 121
    • 84869065974 scopus 로고    scopus 로고
    • ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
    • PMID:22655270
    • Rebagay G, Yan S, Liu C, Cheung N-K. ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy. Front Oncol 2012; 2:34; PMID:22655270; http://dx.doi.org/10.3389/fonc.2012.00034
    • (2012) Front Oncol , vol.2 , pp. 34
    • Rebagay, G.1    Yan, S.2    Liu, C.3    Cheung, N.-K.4
  • 123
    • 84884549747 scopus 로고    scopus 로고
    • Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
    • PMID:24060861
    • Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer 2013; 13:685-700; PMID:24060861; http://dx.doi.org/10.1038/nrc3580
    • (2013) Nat Rev Cancer , vol.13 , pp. 685-700
    • Hallberg, B.1    Palmer, R.H.2
  • 124
    • 46449103344 scopus 로고    scopus 로고
    • TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer
    • PMID:18620092
    • Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 2008; 100:35-83; PMID:18620092; http://dx.doi.org/10.1016/S0065-230X(08)00002-X
    • (2008) Adv Cancer Res , vol.100 , pp. 35-83
    • Linger, R.M.A.1    Keating, A.K.2    Earp, H.S.3    Graham, D.K.4
  • 125
    • 84880354695 scopus 로고    scopus 로고
    • TAM receptors in apoptotic cell clearance, autoimmunity, and cancer
    • PMID:23662598
    • Nguyen K-Q, Tsou W-I, Kotenko S, Birge RB. TAM receptors in apoptotic cell clearance, autoimmunity, and cancer. Autoimmunity 2013; 46:294-7; PMID:23662598; http://dx.doi.org/10.3109/08916934.2013.794515
    • (2013) Autoimmunity , vol.46 , pp. 294-297
    • Nguyen, K.-Q.1    Tsou, W.-I.2    Kotenko, S.3    Birge, R.B.4
  • 126
    • 84877331690 scopus 로고    scopus 로고
    • Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines
    • PMID:23570341
    • Demarest SJ, Gardner J, Vendel MC, Ailor E, Szak S, Huang F, Doern A, Tan X, Yang W, Grueneberg DA, et al. Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines. Biochemistry 2013; 52:3102-18; PMID:23570341; http://dx.doi.org/10.1021/ bi301588c
    • (2013) Biochemistry , vol.52 , pp. 3102-3118
    • Demarest, S.J.1    Gardner, J.2    Vendel, M.C.3    Ailor, E.4    Szak, S.5    Huang, F.6    Doern, A.7    Tan, X.8    Yang, W.9    Grueneberg, D.A.10
  • 127
    • 77957092501 scopus 로고    scopus 로고
    • Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
    • PMID:20809868
    • Linger RMA, Keating AK, Earp HS, Graham DK. Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 2010; 14:1073-90; PMID:20809868; http://dx.doi.org/10.1517/ 14728222.2010.515980
    • (2010) Expert Opin Ther Targets , vol.14 , pp. 1073-1090
    • Linger, R.M.A.1    Keating, A.K.2    Earp, H.S.3    Graham, D.K.4
  • 128
  • 130
    • 84886384644 scopus 로고    scopus 로고
    • Molecular pathways: MERTK signaling in cancer
    • PMID:23833304
    • Cummings CT, Deryckere D, Earp HS, Graham DK. Molecular pathways: MERTK signaling in cancer. Clin Cancer Res 2013; 19:5275-80; PMID:23833304; http://dx.doi.org/10.1158/1078-0432.CCR-12-1451
    • (2013) Clin Cancer Res , vol.19 , pp. 5275-5280
    • Cummings, C.T.1    Deryckere, D.2    Earp, H.S.3    Graham, D.K.4
  • 131
    • 84880922644 scopus 로고    scopus 로고
    • Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer
    • PMID:22890323
    • Linger RMA, Cohen RA, Cummings CT, Sather S, Migdall-Wilson J, Middleton DHG, Lu X, Barón AE, Franklin WA, Merrick DT, et al. Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer. Oncogene 2013; 32:3420-31; PMID:22890323; http://dx.doi.org/10.1038/onc.2012.355
    • (2013) Oncogene , vol.32 , pp. 3420-3431
    • Linger, R.M.A.1    Cohen, R.A.2    Cummings, C.T.3    Sather, S.4    Migdall-Wilson, J.5    Middleton, D.H.G.6    Lu, X.7    Barón, A.E.8    Franklin, W.A.9    Merrick, D.T.10
  • 132
    • 84892724318 scopus 로고    scopus 로고
    • MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation
    • PMID:24165158
    • Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK, Yoon S-J, Park BM, Park E, Bae JH, Choi C-M, et al. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation. Cancer Res 2014; 74:253-62; PMID:24165158; http://dx.doi.org/10. 1158/0008-5472.CAN-13-1103
    • (2014) Cancer Res , vol.74 , pp. 253-262
    • Rho, J.K.1    Choi, Y.J.2    Kim, S.Y.3    Kim, T.W.4    Choi, E.K.5    Yoon, S.-J.6    Park, B.M.7    Park, E.8    Bae, J.H.9    Choi, C.-M.10
  • 134
    • 48549094691 scopus 로고    scopus 로고
    • Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia
    • PMID:18502572
    • Hong C-C, Lay J-D, Huang J-S, Cheng A-L, Tang J-L, Lin M-T, Lai G-M, Chuang S-E. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 2008; 268:314-24; PMID:18502572; http://dx.doi.org/10.1016/j.canlet.2008. 04.017
    • (2008) Cancer Lett , vol.268 , pp. 314-324
    • Hong, C.-C.1    Lay, J.-D.2    Huang, J.-S.3    Cheng, A.-L.4    Tang, J.-L.5    Lin, M.-T.6    Lai, G.-M.7    Chuang, S.-E.8
  • 135
    • 70349705633 scopus 로고    scopus 로고
    • Axl as a potential therapeutic target in cancer: Role of Axl in tumor growth, metastasis and angiogenesis
    • PMID:19633687
    • Li Y, Ye X, Tan C, Hongo J-A, Zha J, Liu J, Kallop D, Ludlam MJC, Pei L. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 2009; 28:3442-55; PMID:19633687; http://dx.doi.org/10.1038/onc.2009.212
    • (2009) Oncogene , vol.28 , pp. 3442-3455
    • Li, Y.1    Ye, X.2    Tan, C.3    Hongo, J.-A.4    Zha, J.5    Liu, J.6    Kallop, D.7    Ludlam, M.J.C.8    Pei, L.9
  • 136
    • 77957109253 scopus 로고    scopus 로고
    • An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
    • PMID:20603615
    • Ye X, Li Y, Stawicki S, Couto S, Eastham-Anderson J, Kallop D, Weimer R, Wu Y, Pei L. An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 2010; 29:5254-64; PMID:20603615; http://dx.doi.org/10.1038/onc.2010.268
    • (2010) Oncogene , vol.29 , pp. 5254-5264
    • Ye, X.1    Li, Y.2    Stawicki, S.3    Couto, S.4    Eastham-Anderson, J.5    Kallop, D.6    Weimer, R.7    Wu, Y.8    Pei, L.9
  • 138
    • 77956268839 scopus 로고    scopus 로고
    • Understanding resistance to EGFR inhibitors-impact on future treatment strategies
    • PMID:20551942
    • Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7:493-507; PMID:20551942; http://dx.doi.org/10.1038/nrclinonc.2010.97
    • (2010) Nat Rev Clin Oncol , vol.7 , pp. 493-507
    • Wheeler, D.L.1    Dunn, E.F.2    Harari, P.M.3
  • 139
    • 73349088416 scopus 로고    scopus 로고
    • Resistance to Trastuzumab in Breast Cancer
    • PMID:20008848
    • Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res 2009; 15:7479-91; PMID:20008848; http://dx.doi.org/10. 1158/1078-0432.CCR-09-0636
    • (2009) Clin Cancer Res , vol.15 , pp. 7479-7491
    • Pohlmann, P.R.1    Mayer, I.A.2    Mernaugh, R.3
  • 140
    • 84896696101 scopus 로고    scopus 로고
    • Resistance to human epidermal growth factor receptor type 2-targeted therapies
    • PMID:24462377
    • Thery J-C, Spano J-P, Azria D, Raymond E, Penault Llorca F. Resistance to human epidermal growth factor receptor type 2-targeted therapies. Eur J Cancer 2014; 50:892-901; PMID:24462377; http://dx.doi.org/10.1016/j.ejca.2014.01.003
    • (2014) Eur J Cancer , vol.50 , pp. 892-901
    • Thery, J.-C.1    Spano, J.-P.2    Azria, D.3    Raymond, E.4    Penault Llorca, F.5
  • 141
    • 80054765331 scopus 로고    scopus 로고
    • A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
    • PMID:22014573
    • Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, Totpal K, Wong A, Lee CV, Stawicki S, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
    • (2011) Cancer Cell , vol.20 , pp. 472-486
    • Schaefer, G.1    Haber, L.2    Crocker, L.M.3    Shia, S.4    Shao, L.5    Dowbenko, D.6    Totpal, K.7    Wong, A.8    Lee, C.V.9    Stawicki, S.10
  • 142
    • 84872525097 scopus 로고    scopus 로고
    • Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation
    • PMID:23172311
    • Huang S, Li C, Armstrong EA, Peet CR, Saker J, Amler LC, Sliwkowski MX, Harari PM. Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res 2013; 73:824-33; PMID:23172311; http://dx.doi.org/10.1158/0008-5472.CAN-12-1611
    • (2013) Cancer Res , vol.73 , pp. 824-833
    • Huang, S.1    Li, C.2    Armstrong, E.A.3    Peet, C.R.4    Saker, J.5    Amler, L.C.6    Sliwkowski, M.X.7    Harari, P.M.8
  • 143
    • 84894145210 scopus 로고    scopus 로고
    • MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors
    • PMID:24282274
    • Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Mol Cancer Ther 2014; 13:410-25; PMID:24282274; http://dx.doi.org/10.1158/1535-7163.MCT-13-0255
    • (2014) Mol Cancer Ther , vol.13 , pp. 410-425
    • Fitzgerald, J.B.1    Johnson, B.W.2    Baum, J.3    Adams, S.4    Iadevaia, S.5    Tang, J.6    Rimkunas, V.7    Xu, L.8    Kohli, N.9    Rennard, R.10
  • 145
    • 83655203270 scopus 로고    scopus 로고
    • Cancer therapy with trifunctional antibodies: Linking innate and adaptive immunity
    • PMID:22149036
    • Hess J, Ruf P, Lindhofer H. Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity. Future Oncol 2012; 8:73-85; PMID:22149036; http://dx.doi.org/10.2217/fon.11.138
    • (2012) Future Oncol , vol.8 , pp. 73-85
    • Hess, J.1    Ruf, P.2    Lindhofer, H.3
  • 146
    • 84866549256 scopus 로고    scopus 로고
    • Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling
    • PMID:22820509
    • Diermeier-Daucher S, Ortmann O, Buchholz S, Brockhoff G. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs 2012; 4:614-22; PMID:22820509; http://dx.doi.org/10. 4161/mabs.21003
    • (2012) MAbs , vol.4 , pp. 614-622
    • Diermeier-Daucher, S.1    Ortmann, O.2    Buchholz, S.3    Brockhoff, G.4
  • 147
    • 84856034032 scopus 로고    scopus 로고
    • Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment
    • PMID:22126733
    • Schroeder P, Lindemann C, Dettmar K, Brieger J, Gosepath J, Pogorzelski B, Seimetz D, Atz J. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 2011; 13:889-98; PMID:22126733; http://dx.doi.org/10.1007/s12094-011-0751-5
    • (2011) Clin Transl Oncol , vol.13 , pp. 889-898
    • Schroeder, P.1    Lindemann, C.2    Dettmar, K.3    Brieger, J.4    Gosepath, J.5    Pogorzelski, B.6    Seimetz, D.7    Atz, J.8
  • 148
    • 84883179862 scopus 로고    scopus 로고
    • Targeting the ERBB family in cancer: Couples therapy
    • PMID:23949426
    • Tebbutt N, Pedersen MW, Johns TG. Targeting the ERBB family in cancer: couples therapy. Nat Rev Cancer 2013; 13:663-73; PMID:23949426; http://dx.doi.org/10.1038/nrc3559
    • (2013) Nat Rev Cancer , vol.13 , pp. 663-673
    • Tebbutt, N.1    Pedersen, M.W.2    Johns, T.G.3
  • 149
    • 79953782986 scopus 로고    scopus 로고
    • Combining epitope-distinct antibodies to HER2: Cooperative inhibitory effects on invasive growth
    • PMID:21132012
    • Emde A, Pradeep C-R, Ferraro DA, Ben-Chetrit N, Sela M, Ribba B, Kam Z, Yarden Y. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 2011; 30:1631-42; PMID:21132012; http://dx.doi.org/10.1038/onc.2010.547
    • (2011) Oncogene , vol.30 , pp. 1631-1642
    • Emde, A.1    Pradeep, C.-R.2    Ferraro, D.A.3    Ben-Chetrit, N.4    Sela, M.5    Ribba, B.6    Kam, Z.7    Yarden, Y.8
  • 150
    • 77955796080 scopus 로고    scopus 로고
    • Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
    • PMID:20616078
    • Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci U S A 2010; 107:13252-7; PMID:20616078; http://dx.doi.org/10.1073/pnas.0913476107
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 13252-13257
    • Spangler, J.B.1    Neil, J.R.2    Abramovitch, S.3    Yarden, Y.4    White, F.M.5    Lauffenburger, D.A.6    Wittrup, K.D.7
  • 151
    • 79960972076 scopus 로고    scopus 로고
    • Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models
    • PMID:21700765
    • Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011; 17:5060-70; PMID:21700765; http://dx.doi.org/10. 1158/1078-0432.CCR-10-2927
    • (2011) Clin Cancer Res , vol.17 , pp. 5060-5070
    • Yamashita-Kashima, Y.1    Iijima, S.2    Yorozu, K.3    Furugaki, K.4    Kurasawa, M.5    Ohta, M.6    Fujimoto-Ouchi, K.7
  • 152
    • 77956602095 scopus 로고    scopus 로고
    • Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response
    • PMID:20716637
    • Dong J, Demarest SJ, Sereno A, Tamraz S, Langley E, Doern A, Snipas T, Perron K, Joseph I, Glaser SM, et al. Combination of two insulin-like growth factor-I receptor inhibitory antibodies targeting distinct epitopes leads to an enhanced antitumor response. Mol Cancer Ther 2010; 9:2593-604; PMID:20716637; http://dx.doi.org/10.1158/1535-7163.MCT-09-1018
    • (2010) Mol Cancer Ther , vol.9 , pp. 2593-2604
    • Dong, J.1    Demarest, S.J.2    Sereno, A.3    Tamraz, S.4    Langley, E.5    Doern, A.6    Snipas, T.7    Perron, K.8    Joseph, I.9    Glaser, S.M.10
  • 153
    • 84886742539 scopus 로고    scopus 로고
    • Management of 'in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy
    • PMID:24192693
    • Cante D, La Porta MR, Franco P, Sciacero P, Girelli GF, Marra A, Numico G, Denaro N, Russi EG, Ricardi U. Management of 'in-field' skin toxicity in head and neck cancer patients treated with combined cetuximab and radiotherapy. Oncology 2013; 85:257-61; PMID:24192693; http://dx.doi.org/10.1159/000355579
    • (2013) Oncology , vol.85 , pp. 257-261
    • Cante, D.1    La Porta, M.R.2    Franco, P.3    Sciacero, P.4    Girelli, G.F.5    Marra, A.6    Numico, G.7    Denaro, N.8    Russi, E.G.9    Ricardi, U.10
  • 154
    • 84900385945 scopus 로고    scopus 로고
    • Antibody-drug conjugates: The chemistry behind empowering antibodies to fight cancer
    • PMID:24319196
    • Drachman JG, Senter PD. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer. Hematology Am Soc Hematol Educ Program 2013; 2013:306-10; PMID:24319196; http://dx.doi.org/10.1182/asheducation-2013.1. 306
    • (2013) Hematology Am Soc Hematol Educ Program , vol.2013 , pp. 306-310
    • Drachman, J.G.1    Senter, P.D.2
  • 155
    • 32944467848 scopus 로고    scopus 로고
    • Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
    • PMID:16452232
    • Burgess T, Coxon A, Meyer S, Sun J, Rex K, Tsuruda T, Chen Q, Ho S-Y, Li L, Kaufman S, et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met- dependent human tumors. Cancer Res 2006; 66:1721-9; PMID:16452232; http://dx.doi.org/10.1158/0008-5472.CAN-05-3329
    • (2006) Cancer Res , vol.66 , pp. 1721-1729
    • Burgess, T.1    Coxon, A.2    Meyer, S.3    Sun, J.4    Rex, K.5    Tsuruda, T.6    Chen, Q.7    Ho, S.-Y.8    Li, L.9    Kaufman, S.10


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.